Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibiotic Development To Get Fresh Push, Not Fresh Ideas, From PCAST

This article was originally published in The Pink Sheet Daily

Executive Summary

Upcoming report from presidential advisors will endorse limited population approval, and government funding mechanisms as part of plan to fight resistance.


Related Content

Lung-MAP Patient Screening Should Translate To Cost-Savings
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway
Recipe For Doubling Innovative Medicines Includes New Approval Pathway, FDA Management Changes
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts